KALA BIO, Inc.KALA

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · kalarx.com

Clinical-stage biopharmaceutical company combining a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform with Orphan Drug- and Fast Track-designated candidates, with an on-premises AI platform-as-a-service business (Researgency.ai) for biotech and pharma clients. It also holds exclusive U.S. distribution rights for Virotek's ophthalmology genetic testing program and is evaluating acquisitions of revenue-generating healthcare businesses.

Recent news

KALA Bio Signs Non-Binding LOI to Acquire Nationwide Telehealth Platform with Approximately $48 Million in Sales Since Inception 2026-09-29 · Newsfile

Track KALA in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer